Related Articles
Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: A molecular case report
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin‑ or irinotecan‑based treatment
DNA hypermethylation of aurora kinase A in hepatitis C virus‑positive hepatocellular carcinoma
Gene expression and effects of orally active derivatives of fluoropyrimidine on gastric and colorectal cancer
Gene reorganisations and expression of c-ras, c-src, c-mos and c-fos oncogenes in Namalwa, Wish and C6 cells.